|
Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry. |
|
|
Consulting or Advisory Role - Celgene; Janssen (I); Takeda |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Celgene; Janssen |
|
|
Research Funding - Celgene; Prothena; Takeda |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Novartis |
Speakers' Bureau - Medicom Worldwide |
|
|
Consulting or Advisory Role - Janssen; Takeda |
|
|
Speakers' Bureau - Amgen; Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Celgene; Janssen |
|
|
Speakers' Bureau - Amgen; Celgene; Millennium; Pharmacyclics |
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Myriad Genetics |
Travel, Accommodations, Expenses - Dava Oncology |
|
|
Consulting or Advisory Role - Celgene |
|
|
Consulting or Advisory Role - EveryFit; Gilead Sciences; Janssen |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Stock and Other Ownership Interests - McKesson |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; EMD Serono; Sandoz; Takeda |